US health care CFO's resuscitation on Obama's Healthcare Reform

30 March 2010

Urgent meetings are being held by the financial leaders of American Healthcare companies in the wake of US President Barack Obama's Healthcare Reform being passed 219 '-212 in the House of Representatives (The Pharma Letters passim). The introduction of this policy heralds a transformation in the fabric of American society, and the way U.S citizens receive medical care has suddenly been revolutionized in a direction which health care chief financial officers (CFOs) cannot afford to ignore.

President Obama himself states: '[It] answers the prayers of every American who has hoped deeply for something to be done about a health care system that works for insurance companies, but not for ordinary people.'

As miraculous as this sounds, the campaigns against the bill have been vehement, and during these unstable economic times not everyone is content with Obama's changes. CFOs need to strategize together to implement a plan that ensures the successful revenue cycle of their organizations. Industry leaders such as Vince Schmidt SVP and CFO of Multicare Health System, Mark Spafford CFO and VP of Health Management Associates, Robert Booth CFO of Summit Medical Group and Larry Dupper CFO of Valley View Hospital are attending a series of closed door meetings at the 'CFO Healthcare Summit US 2010' (Ran by GDS International) in Arizona to discuss at this illustrious occurrence what action needs to be taken, and how.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical